Cell therapy boost for advanced liver disease treatment

A pioneering cell therapy has demonstrated promise in treating advanced liver disease, offering a potential breakthrough for patients facing end-stage conditions. Results from a clinical trial suggest that this intervention may serve as a vital alternative to liver transplants, which are currently limited by donor availability, high costs, and strict patient eligibility requirements.

The human liver possesses a remarkable capacity for self-regeneration; however, severe scarring known as cirrhosis can leave the organ damaged beyond repair. With more than three-quarters of patients diagnosed when the condition is already in an advanced state, cirrhosis contributes to more than 11,000 deaths annually in the UK.

Did You Know? The macrophage therapy was developed following more than a decade of research by the University of Edinburgh’s Professor Stuart Forbes, in collaboration with the Scottish National Blood Transfusion Service.

Understanding the Treatment Mechanism

Scientists at the University of Edinburgh developed this therapy by extracting immune cells from a patient’s own blood. These cells are transformed into mature macrophages—white blood cells that act to clear damaged or infected tissue—and then re-injected into the patient. Once in the liver, these cells work to break down scar tissue, mitigate inflammation, and stimulate the growth of healthy liver cells.

View this post on Instagram about University of Edinburgh, Expert Insight

From Instagram — related to University of Edinburgh, Expert Insight

The MATCH clinical trial tested this approach on 26 patients, while 24 others received standard medical care. After a four-year follow-up period, 70 percent of those treated with the macrophage therapy were living without the need for a liver transplant, compared to 40 percent in the standard care group. Notably, there were eight deaths and zero liver transplants among the treated group, while the standard care group saw nine deaths and five liver transplants.

Expert Insight: According to Dr. Lara Campana of Resolution Therapeutics, the study reveals a key mechanism: the therapy induces a strong anti-inflammatory effect in the blood that correlates directly with improved transplant-free survival. This suggests that the therapy is not only safe—with no serious side effects reported—but also biologically active in reversing the impacts of advanced cirrhosis.

Future Implications for Regenerative Medicine

The research team, which included scientists from the University of Dundee, the Scottish National Blood Transfusion Service, Resolution Therapeutics, Tayside Clinical Research Centre, and Glasgow Royal Infirmary, views these findings as a significant step forward. Professor Stuart Forbes has emphasized the desperate need for alternatives to transplantation, noting that many patients currently face the risk of death while waiting for a donor organ.

Stem Cell Therapy for Liver Disease | Payman’s Journey from England to Mexico

Looking ahead, the development of this technology continues. Resolution Therapeutics, a spinout company co-founded by Professor Forbes in 2020, is currently investigating a new version of the macrophage therapy, known as RTX001, through the ongoing EMERALD clinical trial.

Frequently Asked Questions

What is the primary benefit of this macrophage therapy?
The therapy has shown a significantly lower risk of death or the need for a liver transplant over a four-year period compared to standard medical care.

How does the treatment work?
Immune cells are taken from a patient’s blood, converted into mature macrophages, and re-injected. These cells travel to the liver to break down scar tissue, reduce inflammation, and encourage healthy cell growth.

Are there any major safety concerns?
According to the clinical trial results, no serious side effects were reported in patients treated with the cell therapy.

What impact could the successful adoption of regenerative cell therapies have on the global organ transplant waiting list?